Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico
Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico
复制标题
DOI：
10.1016/s0264-410x(02)00152-4
复制
发表时间：
2002-06-07
期刊：
影响因子：
5.5
通讯作者：
Pattanayak, S
中科院分区：
文献类型：
--
作者：
Whittington, D;Matsui-Santana, O;Pattanayak, S
在墨西哥瓜达拉哈拉，使用支付意愿的概念测量了对一种假想疫苗的私人需求，这种疫苗将为未感染艾滋病毒/艾滋病的成年人提供终生保护。一份91个问题的调查工具由训练有素的计数员使用偶然估价技术对234名18-60岁的成年人进行了调查。我们对私人需求的估计表明，个人期望从这种疫苗中获得相当大的个人利益，并且他们愿意拨出其收入的很大一部分，以便以这种方式保护自己免受艾滋病毒感染。瓜达拉哈拉样本中成年人的平均WTP保守估计为6358比索（669美元），中位数为3000比索（316美元）。对个人WTP决定因素的多变量统计分析表明，收入较高、有配偶或伴侣以及认为感染艾滋病毒的风险较高的个人愿意为疫苗支付更高的费用。年龄较大的受访者则愿意少付钱。这些结果表明，在诸如墨西哥这样的中等收入发展中国家，艾滋病毒/艾滋病疫苗可能有一个潜在的巨大私人市场。这些发现对致力于疫苗的研发工作水平具有重要意义，并且假设这些努力取得成功，对使公众获得疫苗的未来政策也具有重要意义。(C) 2002 Elsevier Science Ltd.版权所有。
The private demand for a hypothetical vaccine that would provide lifetime protection against HIV/AIDS to an uninfected adult was measured in Guadalajara, Mexico, using the concept of willingness to pay (WTP). A 91-question survey instrument was administered by trained enumerators employing contingent valuation techniques to 234 adults, aged 18-60. Our estimates of private demand indicate that individuals anticipate sizable personal benefits from such a vaccine, and that they would be willing to allocate a substantial portion of their income to be protected in this way from HIV infection. A conservative estimate of the mean WTP of adults in the Guadalajara sample is 6358 pesos (US$ 669) and the median is 3000 pesos (US$ 316). A multivariate statistical analysis of the determinants of individuals' WTP shows that individuals with hi-her incomes, with spouses or partners, and with higher perceived risks of becoming infected with HIV are willing to pay more for the vaccine. Older respondents are willing to pay less. These results suggest that there is likely to be a potentially large private market for a HIV/AIDS vaccine in the middle-income developing countries such as Mexico. These findings have important implications both for the level of R&D effort that is devoted to a vaccine and, assuming these efforts are successful, for future policies to make the vaccine available to the public. (C) 2002 Elsevier Science Ltd. All rights reserved.